
ESG Advisory Market Size, Share, & Industry Analysis Report: By Type (Environmental Advisory, Social Responsibility Advisory), By Application, By Industry, By Size, and By Region – Market Forecast, 2025–2034
Description
The ESG advisory market size is expected to reach USD 135.90 billion by 2034, according to a new study by Polaris Market Research. The report “ESG Advisory Market Share, Size, Trends, Industry Analysis Report: By Type (Environmental Advisory, Social Responsibility Advisory), By Application, By Industry, By Size, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
ESG advisory is a professional service that guides organizations in adopting sustainability, ethical governance, and social responsibility into their core decision-making processes. The integration of ESG metrics into long-term corporate strategy and value-creation models is boosting growth opportunities. Companies are adopting ESG as a strategic imperative to manage risks, improve brand reputation, and align with stakeholder values in sustainable finance as they move beyond basic compliance. Additionally, ESG advisors play a crucial role in helping businesses identify material issues, develop actionable roadmaps, and ensure that sustainability becomes a driver of competitive advantage throughout the organization.
The increasing demand for data-driven ESG solutions, driven by the need for transparent, measurable, and verifiable outcomes, further drives the expansion opportunities. Companies are under growing pressure to demonstrate real impact through credible metrics and standardized reporting frameworks. This has driven ESG advisory firms to enhance their analytical capabilities, leveraging digital transformation and performance benchmarks to deliver more in-depth insights. The focus on measurable ESG performance is expected to boost, reinforcing the role of advisory services in ensuring data integrity and strategic alignment as expectations from investors, regulators, and consumers evolve.
ESG advisory Market Report Highlights
In terms of application, the strategy development and integration services segment accounted for the largest market share, reflecting organizations' growing focus on embedding ESG principles into their fundamental business models and operational frameworks.
Based on type, the ESG reporting and disclosure segment is anticipated to experience the most rapid expansion in the coming years, due to the swift advancement of global regulatory standards and heightened investor demand for corporate transparency.
North America led the ESG advisory market in revenue share during 2024, attributed to its well-established regulatory infrastructure, active investor engagement, and robust institutional emphasis on ESG adherence.
Asia Pacific is expected to register substantial growth over the forecast period, driven by increasing environmental consciousness, dynamic regulatory developments, and expanding international investor interest in regional sustainability initiatives.
A few global key market players include Bain & Company, Inc.; Boston Consulting Group; Deloitte Touche Tohmatsu Limited; Ernst & Young Global Limited; McKinsey & Company; MSCI Inc.; Nexio Projects; PwC; Sustainalytics; and The ERM International Group Limited.
Polaris Market Research has segmented the market report on the basis of type, application, industry, size, and region:
By Type Outlook (Revenue, USD Billion, 2020–2034)
Environmental Advisory
Social Responsibility Advisory
Governance & Ethics Advisory
ESG Reporting & Disclosure
By Application Outlook (Revenue, USD Billion, 2020–2034)
Strategy Development & Integration
Compliance & Risk Management
Reporting & Transparency
Stakeholder Engagement
By Industry Outlook (Revenue, USD Billion, 2020–2034)
Energy & Utilities
Manufacturing
Financial Services
Technology
Healthcare
By Size Outlook (Revenue, USD Billion, 2020–2034)
Large Enterprises
Medium Businesses
Small Businesses
By Regional Outlook (Revenue, USD Billion, 2020–2034)
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
ESG advisory is a professional service that guides organizations in adopting sustainability, ethical governance, and social responsibility into their core decision-making processes. The integration of ESG metrics into long-term corporate strategy and value-creation models is boosting growth opportunities. Companies are adopting ESG as a strategic imperative to manage risks, improve brand reputation, and align with stakeholder values in sustainable finance as they move beyond basic compliance. Additionally, ESG advisors play a crucial role in helping businesses identify material issues, develop actionable roadmaps, and ensure that sustainability becomes a driver of competitive advantage throughout the organization.
The increasing demand for data-driven ESG solutions, driven by the need for transparent, measurable, and verifiable outcomes, further drives the expansion opportunities. Companies are under growing pressure to demonstrate real impact through credible metrics and standardized reporting frameworks. This has driven ESG advisory firms to enhance their analytical capabilities, leveraging digital transformation and performance benchmarks to deliver more in-depth insights. The focus on measurable ESG performance is expected to boost, reinforcing the role of advisory services in ensuring data integrity and strategic alignment as expectations from investors, regulators, and consumers evolve.
ESG advisory Market Report Highlights
In terms of application, the strategy development and integration services segment accounted for the largest market share, reflecting organizations' growing focus on embedding ESG principles into their fundamental business models and operational frameworks.
Based on type, the ESG reporting and disclosure segment is anticipated to experience the most rapid expansion in the coming years, due to the swift advancement of global regulatory standards and heightened investor demand for corporate transparency.
North America led the ESG advisory market in revenue share during 2024, attributed to its well-established regulatory infrastructure, active investor engagement, and robust institutional emphasis on ESG adherence.
Asia Pacific is expected to register substantial growth over the forecast period, driven by increasing environmental consciousness, dynamic regulatory developments, and expanding international investor interest in regional sustainability initiatives.
A few global key market players include Bain & Company, Inc.; Boston Consulting Group; Deloitte Touche Tohmatsu Limited; Ernst & Young Global Limited; McKinsey & Company; MSCI Inc.; Nexio Projects; PwC; Sustainalytics; and The ERM International Group Limited.
Polaris Market Research has segmented the market report on the basis of type, application, industry, size, and region:
By Type Outlook (Revenue, USD Billion, 2020–2034)
Environmental Advisory
Social Responsibility Advisory
Governance & Ethics Advisory
ESG Reporting & Disclosure
By Application Outlook (Revenue, USD Billion, 2020–2034)
Strategy Development & Integration
Compliance & Risk Management
Reporting & Transparency
Stakeholder Engagement
By Industry Outlook (Revenue, USD Billion, 2020–2034)
Energy & Utilities
Manufacturing
Financial Services
Technology
Healthcare
By Size Outlook (Revenue, USD Billion, 2020–2034)
Large Enterprises
Medium Businesses
Small Businesses
By Regional Outlook (Revenue, USD Billion, 2020–2034)
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
125 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source
- 4. Global Epilepsy Drugs Market Insights
- 4.1. Epilepsy Drugs Market – Market Snapshot
- 4.2. Epilepsy Drugs Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Prevalence of Epilepsy
- 4.2.1.2. Advancements in Antiepileptic Drug Development
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Drug resistance in a significant percentage of epilepsy patients
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Epilepsy Drugs Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Global Epilepsy Drugs Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 5.3. First Generation Anti-epileptics
- 5.3.1. Global Epilepsy Drugs Market, by First Generation Anti-epileptics, by Region, 2020–2034 (USD Billion)
- 5.4. Second Generation Anti-epileptics
- 5.4.1. Global Epilepsy Drugs Market, by Second Generation Anti-epileptics, by Region, 2020–2034 (USD Billion)
- 5.5. Third Generation Anti-epileptics
- 5.5.1. Global Epilepsy Drugs Market, by Third Generation Anti-epileptics, by Region, 2020–2034 (USD Billion)
- 6. Global Epilepsy Drugs Market, by Route of Administration
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 6.3. Oral
- 6.3.1. Global Epilepsy Drugs Market, by Oral, by Region, 2020–2034 (USD Billion)
- 6.4. Intravenous
- 6.4.1. Global Epilepsy Drugs Market, by Intravenous, by Region, 2020–2034 (USD Billion)
- 6.5. Intra-muscular
- 6.5.1. Global Epilepsy Drugs Market, by Intra-muscular, by Region, 2020–2034 (USD Billion)
- 7. Global Epilepsy Drugs Market, by Antiepileptic Drugs Type
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 7.3. Narrow-Spectrum AEDs
- 7.3.1. Global Epilepsy Drugs Market, by Narrow-Spectrum AEDs, by Region, 2020–2034 (USD Billion)
- 7.4. Broad-Spectrum AEDs
- 7.4.1. Global Epilepsy Drugs Market, by Broad-Spectrum AEDs, by Region, 2020–2034 (USD Billion)
- 8. Global Epilepsy Drugs Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Epilepsy Drugs Market Assessment, By Geography, 2020–2034 (USD Billion)
- 8.3. Epilepsy Drugs Market – North America
- 8.3.1. North America: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.3.2. North America: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.3.3. North America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.3.4. Epilepsy Drugs Market – U.S.
- 8.3.4.1. U.S.: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.3.4.2. U.S.: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.3.4.3. U.S.: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.3.5. Epilepsy Drugs Market – Canada
- 8.3.5.1. Canada: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.3.5.2. Canada: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.3.5.3. Canada: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.4. Epilepsy Drugs Market – Europe
- 8.4.1. Europe: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.4.2. Europe: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.4.3. Europe: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.4.4. Epilepsy Drugs Market – UK
- 8.4.4.1. UK: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.4.4.2. UK: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.4.4.3. UK: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.4.5. Epilepsy Drugs Market – France
- 8.4.5.1. France: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.4.5.2. France: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.4.5.3. France: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.4.6. Epilepsy Drugs Market – Germany
- 8.4.6.1. Germany: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.4.6.2. Germany: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.4.6.3. Germany: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.4.7. Epilepsy Drugs Market – Italy
- 8.4.7.1. Italy: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.4.7.2. Italy: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.4.7.3. Italy: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.4.8. Epilepsy Drugs Market – Spain
- 8.4.8.1. Spain: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.4.8.2. Spain: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.4.8.3. Spain: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.4.9. Epilepsy Drugs Market – Netherlands
- 8.4.9.1. Netherlands: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.4.9.2. Netherlands: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.4.9.3. Netherlands: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.4.10. Epilepsy Drugs Market – Russia
- 8.4.10.1. Russia: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.4.10.2. Russia: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.4.10.3. Russia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.4.11. Epilepsy Drugs Market – Rest of Europe
- 8.4.11.1. Rest of Europe: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.4.11.2. Rest of Europe: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.4.11.3. Rest of Europe: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.5. Epilepsy Drugs Market – Asia Pacific
- 8.5.1. Asia Pacific: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.5.2. Asia Pacific: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.5.3. Asia Pacific: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.5.4. Epilepsy Drugs Market – China
- 8.5.4.1. China: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.5.4.2. China: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.5.4.3. China: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.5.5. Epilepsy Drugs Market – India
- 8.5.5.1. India: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.5.5.2. India: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.5.5.3. India: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.5.6. Epilepsy Drugs Market – Malaysia
- 8.5.6.1. Malaysia: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.5.6.2. Malaysia: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.5.6.3. Malaysia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.5.7. Epilepsy Drugs Market – Japan
- 8.5.7.1. Japan: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.5.7.2. Japan: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.5.7.3. Japan: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.5.8. Epilepsy Drugs Market – Indonesia
- 8.5.8.1. Indonesia: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.5.8.2. Indonesia: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.5.8.3. Indonesia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.5.9. Epilepsy Drugs Market – South Korea
- 8.5.9.1. South Korea: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.5.9.2. South Korea: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.5.9.3. South Korea: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.5.10. Epilepsy Drugs Market – Australia
- 8.5.10.1. Australia: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.5.10.2. Australia: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.5.10.3. Australia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.5.11. Epilepsy Drugs Market – Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.5.11.2. Rest of Asia Pacific: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.5.11.3. Rest of Asia Pacific: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.6. Epilepsy Drugs Market – Middle East & Africa
- 8.6.1. Middle East & Africa: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.6.2. Middle East & Africa: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.6.3. Middle East & Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.6.4. Epilepsy Drugs Market – Saudi Arabia
- 8.6.4.1. Saudi Arabia: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.6.4.2. Saudi Arabia: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.6.4.3. Saudi Arabia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.6.5. Epilepsy Drugs Market – UAE
- 8.6.5.1. UAE: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.6.5.2. UAE: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.6.5.3. UAE: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.6.6. Epilepsy Drugs Market – Israel
- 8.6.6.1. Israel: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.6.6.2. Israel: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.6.6.3. Israel: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.6.7. Epilepsy Drugs Market – South Africa
- 8.6.7.1. South Africa: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.6.7.2. South Africa: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.6.7.3. South Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.6.8. Epilepsy Drugs Market – Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.6.8.2. Rest of Middle East & Africa: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.6.8.3. Rest of Middle East & Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.7. Epilepsy Drugs Market – Latin America
- 8.7.1. Latin America: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.7.2. Latin America: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.7.3. Latin America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.7.4. Epilepsy Drugs Market – Mexico
- 8.7.4.1. Mexico: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.7.4.2. Mexico: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.7.4.3. Mexico: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.7.5. Epilepsy Drugs Market – Brazil
- 8.7.5.1. Brazil: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.7.5.2. Brazil: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.7.5.3. Brazil: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.7.6. Epilepsy Drugs Market – Argentina
- 8.7.6.1. Argentina: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.7.6.2. Argentina: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.7.6.3. Argentina: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 8.7.7. Epilepsy Drugs Market – Rest of Latin America
- 8.7.7.1. Rest of Latin America: Epilepsy Drugs Market, by Type, 2020–2034 (USD Billion)
- 8.7.7.2. Rest of Latin America: Epilepsy Drugs Market, by Route of Administration, 2020–2034 (USD Billion)
- 8.7.7.3. Rest of Latin America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020–2034 (USD Billion)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. Abbott Laboratories
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Eisai Co., Ltd.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. GlaxoSmithKline plc
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Jazz Pharmaceuticals plc
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Neurelis Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Novartis AG
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Pfizer Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Sanofi
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Sun Pharmaceutical Industries Limited
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Pharma)
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Takeda Pharmaceutical Company
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. UCB S.A.
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.